Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) is now available.
Pharmaron Beijing Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its governance structure by formulating appraisal standards and remuneration policies for its directors and senior management. This initiative aims to optimize corporate governance and ensure accountability within the company’s leadership, potentially strengthening its industry position and stakeholder trust.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. operates in the pharmaceutical industry, focusing on providing comprehensive drug research and development services. The company is known for its expertise in drug discovery, preclinical, and clinical development services, catering to a global market.
Average Trading Volume: 13,234,723
Technical Sentiment Signal: Buy
Current Market Cap: HK$59.02B
Find detailed analytics on 3759 stock on TipRanks’ Stock Analysis page.